Targeting A2 adenosine receptors in cancer

Tumor cells use various ways to evade anti‐tumor immune responses. Adenosine, a potent immunosuppressive metabolite, is often found elevated in the extracellular tumor microenvironment. Therefore, targeting adenosine‐generating enzymes (CD39 and CD73) or adenosine receptors has emerged as a novel means to stimulate anti‐tumor immunity. In particular, the A2 (A2a and A2b) adenosine receptors exhibit similar immunosuppressive and pro‐angiogenic functions, yet have distinct biological roles in cancer. In this review, we describe the common and distinct biological consequences of A2a and A2b adenosine receptor signaling in cancer. We discuss recent pre‐clinical studies and summarize the different mechanisms‐of‐action of adenosine‐targeting drugs. We also review the rationale for combining inhibitors of the adenosine pathway with other anticancer therapies such immune checkpoint inhibitors, tumor vaccines, chemotherapy and adoptive T cell therapy.